< Back to previous page


Programmed death-1 as novel immunotherapeutic target in malignant pleural mesothelioma : investigation of cancer drug of the year 2013.

The prognosis of malignant pleural mesothelioma (MPM) patients remains dismal with a median overall survival of only 9-12 months. The immune system plays a critica I role in protection against MPM with preliminary clinical evidence that immunotherapy can lead to MPM contro!. Here, we will be the first to investigate the immune checkpoint programmed-death 1 (PD-1) and its ligands as novel and potentially highly effective immunotherapeutic targets in MPM.
Date:1 Jan 2015  →  31 Dec 2016
Disciplines:Immunology, Morphological sciences, Oncology